Piramal Pharma declines after US FDA issues Form 483 with 6 observations to Turbhe unit
Piramal Pharma slipped 1.14% to Rs 195.40 after the US FDA issued a Form-483 with 6 observations to the company's Turbhe facility post a GMP inspection.
complianceg5 天
Be Prepared for Your Journey with The FDA – How to Be Inspection-Ready
Ensure your FDA inspection readiness with expert guidance! Learn how to navigate audits, maintain compliance, and implement effective CAPA strategies.
Med Device Online1 天
Mastering FDA Inspections: The Prep Work For Regulatory Success
In the medical device industry, FDA inspections are not a regulatory hurdle — they are a powerful tool for improving product ...
FiercePharma2 天
FDA hits pair of Indian API makers with warning letters, import alerts
From turning away inspectors to falsifying data and leaving "bare footprints" in production containers, two of the latest ...
Piramal Pharma shares in focus after US FDA issues six observations for Mumbai facility
Piramal Pharma shares will be in focus after the US FDA's GMP inspection at its Turbhe facility from February 11-17, 2025, ...
Daily3 天
USFDA issues 6 observations for Piramal Pharma Turbhe facility
Mumbai: Piramal Pharma has announced that the Company has received six observations from US Food and Drug Administration ...
Daily1 天
USFDA issues 2 observations for Cipla arm Mahape facility
Mumbai: Cipla, an Indian multinational pharmaceutical company, has announced that the United States Food and Drugs ...
India Infoline4 天
Piramal Pharma’s Turbhe Facility Gets US FDA Observations
The observations are mainly procedural and do not indicate any data integrity issues, Piramal Pharma added in a regulatory ...